Difficulty: Medium
Average Score: 76%
Practice
Colchicine may be an effective drug to prevent the development of AA amyloidosis in which of the following diseases?
Correct answer
C
Rationale
Colchicine is an anti-inflammatory medication that is known to be effective in preventing the development of AA amyloidosis, a condition characterized by the deposition of amyloid protein in organs. In this case, the correct answer is C) familial Mediterranean fever (FMF). FMF is an autosomal recessive disease characterized by recurrent episodes of fever, serositis, and arthritis. One of the complications of FMF is the development of AA amyloidosis due to chronic inflammation. Colchicine is the mainstay treatment for FMF and has been shown to reduce the frequency of acute attacks and the risk of developing AA amyloidosis.
Option A) juvenile idiopathic arthritis is incorrect because colchicine is not typically used in the treatment of this condition. Juvenile idiopathic arthritis is usually managed with nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) depending on the subtype.
Option B) ankylosing spondylitis is also incorrect as colchicine is not a standard treatment for this condition. Ankylosing spondylitis is managed with NSAIDs, physical therapy, and in some cases, biologic agents like TNF-alpha inhibitors.
Option D) hyper IgD syndrome is incorrect because colchicine is not indicated for this genetic autoinflammatory disorder. Hyper IgD syndrome is managed symptomatically, and colchicine is not a primary treatment for this condition.
Educationally, understanding the use of colchicine in preventing AA amyloidosis in FMF highlights the importance of appropriate medication choices based on the underlying pathophysiology of a disease. It also emphasizes the significance of recognizing the role of inflammation in certain diseases and how targeted therapies like colchicine can help prevent serious complications like amyloidosis.
Option A) juvenile idiopathic arthritis is incorrect because colchicine is not typically used in the treatment of this condition. Juvenile idiopathic arthritis is usually managed with nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) depending on the subtype.
Option B) ankylosing spondylitis is also incorrect as colchicine is not a standard treatment for this condition. Ankylosing spondylitis is managed with NSAIDs, physical therapy, and in some cases, biologic agents like TNF-alpha inhibitors.
Option D) hyper IgD syndrome is incorrect because colchicine is not indicated for this genetic autoinflammatory disorder. Hyper IgD syndrome is managed symptomatically, and colchicine is not a primary treatment for this condition.
Educationally, understanding the use of colchicine in preventing AA amyloidosis in FMF highlights the importance of appropriate medication choices based on the underlying pathophysiology of a disease. It also emphasizes the significance of recognizing the role of inflammation in certain diseases and how targeted therapies like colchicine can help prevent serious complications like amyloidosis.